Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HuMAB companies -- Ignore unavailable to you. Want to Upgrade?

To: Chi Wong who wrote (25)	7/5/2000 1:35:08 PM
From: Return to Sender	Respond to of 1022

Monoclonal antibodies were referred to as magic bullets back when it was believed that they could easily target cancer and the like for both diagnosis and treatment. It became quite clear that while murine (mouse), or somewhat humanized monoclonal antibodies that there usefulness would be limited because our own immune systems would destroy the MABs before they could fully accomplish whatever treatment the companies had in mind for the particular antibody. Now with fully humanized antibodies we have hope that we will finally see some truly exceptional results from the companies who have fully humanized MABs in clinical trials. It is believed that these antibodies will remain active long enough to have real therapeutic effects. For what it's worth here is an updated list of some of the companies carrying on research in this area that I found at the Bull Sector site: ABGX AHP ALXN BBIOY BGEN BTRN CLL CYPH DNA IDPH ILXO IMGN IMMU MABA MEDI MEDX MLNM NVS PDLI PGNX TNOX XOMA bullsector.com RTS